INA’s response to the spread of COVID-19 (SARS-CoV-2) Novel Coronavirus infections in Japan
With the health safety and security of all stakeholders including employees and customers as our top priority, Ina Research (INA) has been implementing measures based on guidance received from government authorities in order to help prevent the spread of COVID-19 (SARS-CoV-2) infections. COVID-19 is the most urgent social concern in the world. However, comparing with European countries and US or China, the COVID-19 infection overshoot has not appeared in Japan as of today (March 25, 2020). Needless to say, we are never off our guard and protection to maintain all contracted studies in operation and all future studies. Animal Rooms: We, INA has highly advanced technologies such as One-by-One Animal
Information about entering into an agency contract with SAGE HEALTHCARE PTE LTD.
Ina Research Co., Ltd. (hereinafter “the Company”) has decided today to enter into an agency contract with SAGE HEALTHCARE PTE LTD (hereinafter “SAGE”) in Singapore for the purpose of expanding sales of non-clinical studies focusing on pharmaceuticals. Information about entering into an agency contract with SAGE HEALTHCARE PTE LTD. – PDF (132KB)
Announcement concerning the start of agency business with ViruSure
Ina Research Inc. (hereinafter referred to as “our company”) is pleased to announce that our company has decided to start the agency business for ViruSure (Austria : hereinafter referred to as “VS”), which is a contract research organization (hereinafter referred to as “CRO” ) in Japan and Taiwan today. (Please refer to the below PDF file for more details.) Announcement concerning the start of agency business with ViruSure GmbH (PDF: 128KB)
Agency Agreement with Level Biotechnology Inc., Taiwan
Ina Research Inc. (INA) is pleased to announce the signing of an agency agreement with Level Biotechnology Inc. (LBI), a Taiwanese Contract Research Organization. 1.Market Potential The biopharmaceutical industry in Taiwan is currently growing at an unprecedented rate. With LBI as our locally-based agent, Taiwanese customers can now access INAs services in nonhuman primates, studies which are required as part of the biopharmaceutical development process. In this way, INA hopes to establish a mutually-complementary relationship with LBI, and make inroads into this growing market. 2. About LBI (1) Company Name: Level Biotechnology Inc. (2) Address: No. 80, Lane 169, Kangning St., His-Chih Dist., New Taipei City 221, Taiwan R.O.C. (3)
Tokyo University AMED iD3 Catalyst Unit posted about Grobal SEND Alliance.
A column regarding to the Grobal SEND Alliance (G-SEND) was posted on the website of Tokyo University AMED iD3 Catalyst Unit. G-SEND is a non-profit consortium, consisting of CROs from Japan, South Korea, Taiwan, Singapore, the US and Switzerland. They provide SEND data sets which are created in a standardized process and Ina Reseach is the central CRO as their base. Please see the link below for the article: http://www.id3catalyst.jp/e/column03.html
Nature publishes the result of a study on a myocardial infarction treatment using iPS cells
With the goal of developing a new treatment for myocardial infarction, Ina Research has been pursuing a joint research project with a research team led by Associate Professor Yuji Shiba of the Institute for Biomedical Sciences (Director: Naoto Saito), Interdisciplinary Cluster for Cutting Edge Research at Shinshu University (hereinafter referred to as the “Shiba research team”) (as reported in a press release dated August 17, 2015). Today, I am pleased to inform you that the project’s achievements have been recognized and an article written by Associate Professor Yuji Shiba as lead author, and an employee of Ina Research as coauthor, will be published in the British multidisciplinary scientific journal Nature
Ina Research, Japan SLC, and DNA Link join forces for the effective use of PDX mouse models
Ina Research, Japan SLC, and DNA Link join forces for the effective use of PDX mouse modelsFirst-ever production and commercial use in Japan July 2018, Ina Research, Japan SLC, and Korea’s DNA Link launched a joint project for the effective use of “PDX (Patient derived xenograft) mouse models,” in which patient-derived cancer cells are transplanted into the living body of a mouse for the development of pharmaceutical products. Japan SLC, a provider of laboratory animals, will produce PDX models using cancer cells of Asian patients provided by DNA Link, which owns the library of human cancer cells.Ina Research will then use the optimal PDX model to conduct drug efficacy tests
Shinanomainichi news posted about new research project for CAR-T cell therapy.
Shinshu University establishes a domestic base in Ina toward the practical application of new cancer treatment “CAR-T cell therapy” Shinano Mainichi News as of September 21, 2018 Translated by Ina Research Shinshu University (headquartered in Matsumoto City) will establish a “Gene/Cell Therapy Research and Development Center” (tentative name), a facility for safety studies of “CAR-T cell therapy,” a new immune cell therapy for cancer, at Ina Research Inc. (Ina City) according to a source on September 20. The center will also provide services including safety studies of medical products. The center is planned to become fully operational in fiscal 2019. It was initiated as a government-commissioned project aimed at improving